23218-93-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-5-nitrobenzoic acid methyl ester is utilized as an intermediate in the organic synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Dye Industry:
In the dye industry, 3-Amino-5-nitrobenzoic acid methyl ester serves as an intermediate for the production of dyes. Its chemical properties make it suitable for the synthesis of a range of colorants used in various applications, including textiles, plastics, and printing inks.
Used in Agrochemical Industry:
3-Amino-5-nitrobenzoic acid methyl ester is also employed as an intermediate in the agrochemical sector. It plays a role in the synthesis of compounds used in the development of pesticides and other agricultural chemicals, thereby contributing to crop protection and enhancement of agricultural productivity.

InChI:InChI=1/C8H8N2O4/c1-14-8(11)5-2-6(9)4-7(3-5)10(12)13/h2-4H,9H2,1H3

Upstream product

• 2702-58-1 methyl 3,5-dinitrobenzoate 
• 99-34-3 3,5-dinitrobenzoic acid 
• 67-56-1 methanol 
• 618-84-8 3-amino-5-nitro-benzoic acid 
• 99-33-2 3,5-dinitrobenoyl chloride 

Downstream Products

• 99066-80-5 methyl 3-cyano-5-nitrobenzoate 
• 36138-28-0 3-chloro-5-nitro-benzoic acid methyl ester 
• 14622-17-4 methyl 3-acetamido-5-nitrobenzoate 
• 35487-17-3 1-methylimidazolium chloride 
• 909401-93-0 3-nitro-5-phenylacetylamino-benzoic acid methyl ester 
• 706791-78-8 3-(4-chlorobutanoylamino)-5-nitrobenzoic acid methyl ester 
• 936719-22-1 5-nitro-3-carboxymethylphenylisocyanate 
• 1452402-89-9 methyl 3-acetamido-5-azidobenzoate 
• 1452402-90-2 3-acetamido-5-azidobenzoic acid 
• 1949-55-9 methyl 3,5-diaminobenzoate 
• 632626-89-2 3-(1,1-dioxo-1/⁶-isothiazolidin-2-yl)-5-nitrobenzoic acid methyl ester 

Relevant academic research and scientific papers

FE NANOPARTICLES WITH PPM CONTENTS OF PD, CU AND/OR NI, REACTIONS IN WATER CATALYZED BY THEM

The present application discloses a nanoparticle composition prepared from a mixture comprising: a) a transition metal salt; b) an iron salt; and c) a reducing agent; and methods for the use of such compositions, including the reduction of an organic compound comprising a nitro group to form an organic compound comprising an amine group, the Cu-catalyzed cyclization of an azide and an alkyne (click chemistry) and cross coupling reactions, notably Suzuki-Miyaura reactions. The transition metal salts are in particular Pd, Cu and Ni salts, the content of these metals being typically in the ppm range based on the major constituent Fe in the final products.

Design of photoaffinity labeling probes derived from 3,4,5-trimethylfuran-2(5H)-one for mode of action elucidation

Herein we report the synthesis of new probes for photoaffinity labeling with the aim of receptor identification and mode of action elucidation of 3,4,5-trimethylfuran-2(5H)-one (TMB), recently identified in the smoke of burning vegetation as an efficient seed germination inhibitor. These photoaffinity probes consist of an ethynyl group that acts as a tag for introduction of an optional detectable marker unit by an appropriate chemoselective ligation method after the photo-cross-linking operation.

Bioreduction of aryl azides during mutasynthesis of new ansamitocins

Supplementing a culture of a mutant strain of Actinosynnema pretiosum that is unable to biosynthesize aminohydroxy benzoic acid (AHBA), with 3-azido-5-hydroxy-benzoic acid and 3-azido-5-amino-benzoic acid, unexpectedly yielded anilino ansamitocins instead

Zinc phthalocyanine with PEG-400 as a recyclable catalytic system for selective reduction of aromatic nitro compounds

Zinc phthalocyanine with PEG-400 was established as a catalytic system for chemo and regioselective reduction of aromatic nitro compounds to corresponding amines. A large range of reducible functional groups such as acid, amide, ester, halogen, lactone, nitrile, N-benzyl, O-benzyl, hydroxy and heterocycles were well tolerated. Direct synthesis of benzotriazole from O-dinitrobenzene was achieved for the first time. The present catalytic system was successfully employed for the reduction of carbonyl and ester compounds to corresponding alcohols and reductive amination of benzaldehydes with primary amines to form corresponding secondary amines. Remarkable advantages of the present catalytic method include low loading of metal, avoidance of toxic ligands and high isolated yields. The catalyst was recyclable up to four times without any loss of selectivity and activity.

Pteridinone derivatives as PI3-kinases inhibitors

New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

BACE-1 inhibitors Part 1: Identification of novel hydroxy ethylamines (HEAs)

Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. Herein, is described the lead generation effort which resulted, with the support of X-ray crystallography, in the discovery of pot

Second generation of hydroxyethylamine BACE-1 inhibitors: Optimizing potency and oral bioavailability

BACE-1 inhibition has the potential to provide a disease-modifying therapy for the treatment of Alzheimer's disease. Optimization of a first generation of BACE-1 inhibitors led to the discovery of novel hydroxyethylamines (HEAs) bearing a tricyclic nonprime side. These derivatives have nanomolar cell potency and are orally bioavailable.

β SECRETASE INHIBITOR

Disclosed is a compound represented by the formula (1) below which is useful as a drug for treating Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (1) [In the formula, R1 represents a group represented by the following formula (2): (2) (wherein X represents a nitrogen atom or a group expressed as C(R5); Y represents a nitrogen atom or a group expressed as C(R6); and R5 and R6 independently represent a hydrogen atom or the like) or the like; m represents an integer of 1-6; L1 represents a single bond or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like; R3 represents a hydrogen atom or the like; L2 represents a single bond or the like; and R4 represents a hydrogen atom, a substituted or unsubstituted aryl group or the like.]

CONTRAST AGENTS AND DIAGNOSTIC COMPOSITIONS BASED ON IODINE-CONTAINING CYANURIC ACID DERIVATIVES

The present invention relates to a class of compounds of Formula (I) and to diagno stic compositions containing such compounds where the compounds are iodine conta ining compounds. More specifically the iodine containing compounds are chemical compounds containing a cyanuric acid scaffolding moiety allowing for the arrange ment of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imag ing and in particular in X-ray imaging and to contrast media containing such com pounds .

HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.